Q-omics provides the consensus-scored CCDC37-DT profile across patient tissues and cancer cell-line models. CCDC37-DT expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CCDC37-DT is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, CCDC37-DT RNA expression shows 6,538 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, and STAD as cancer lineages where CCDC37-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC37-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC37-DT survival associations across molecular data types. CCDC37-DT RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC37-DT RNA expression–survival associations across cancer types. High CCDC37-DT expression shows unfavorable associations in BRCA, ACC, READ, LIHC, MESO and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CCDC37-DT RNA expression.
This table summarizes CCDC37-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC37-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC37-DT shows lower tumor expression in BRCA. The BRCA box plot shows higher CCDC37-DT RNA expression in normal versus tumor tissue (log2 FC = −0.114, t-test p = .001).
This table shows molecular features associated with CCDC37-DT in patient tissues and cancer cell lines. In patient samples, CCDC37-DT shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
